Why is this Clinical Research Study Important?

Alopecia areata is a condition that causes hair loss on the scalp and/or body, with patchy hair loss affecting the scalp being the most common type. This often occurs in cycles of unpredictable hair loss and spontaneous regrowth. Nearly 2% of the general population will be affected by alopecia areata at some point in their lifetimes. In some cases, alopecia areata can be associated with high rates of depression and anxiety. The investigational oral drug is intended to treat the underlying autoimmune process that results in hair loss from alopecia areata. There is currently no approved medication that treats the cause of hair loss from alopecia areata.

Before new medications can be approved for public use, they must be tested in clinical research studies like this one. The THRIVE clinical study will look at the safety and effectiveness of the investigational oral drug on hair loss associated with alopecia areata.